How will Cedrus Group facilitate market entry for foreign life sciences firms in China?

Question

Accepted Answer

Cedrus Group to Facilitate China Market Entry for Foreign Life Sciences Firms Through Strategic Partnership with Xiuzheng Pharmaceutical Group

Cedrus Group will facilitate market entry for foreign life sciences firms in China by leveraging its established expertise in bringing innovative technologies and products to the Greater China region, coupled with a new collaboration agreement with Xiuzheng Pharmaceutical Group. This partnership aims to identify and invest in leading global innovators, providing them with a trusted pathway for expansion into the Chinese market, supported by both Cedrus's global financial and advisory capabilities and Xiuzheng's extensive local resources. An investment committee has been formed by both entities to assess a robust pipeline of opportunities.
Leveraging Global Connectivity and Investment Banking Services

Cedrus Group will deploy its distinguished investment banking services and capitalize on its European headquarters in Zurich to act as a holistic enabler and connector. This involves facilitating cross-border transactions and utilizing its global connectivity across the life sciences industry to bring overseas technologies and products to China. The group has over a decade of experience in this area, identifying visionary companies seeking early access to the Chinese pharmaceutical market.
Providing Local Support Through Xiuzheng Pharmaceutical Group

Xiuzheng Pharmaceutical Group will offer crucial support for opportunities introduced to China, including comprehensive clinical trials advisory services. Furthermore, Xiuzheng will provide access to its manufacturing partners and utilize its experienced workforce for the marketing and distribution of products within the Chinese market. Xiuzheng, a renowned Chinese pharmaceutical major, operates 130 subsidiaries and employs over 100,000 individuals, possessing more than 2,000 references of medicines and health foods.
Strategic Investment and Advisory for Growth

The collaboration is centered on assessing and conducting direct investments in the life sciences industry, with a specific focus on investing in the world's leading innovators. Cedrus will offer investment and ongoing advisory services to these companies, supporting their market entry and subsequent growth within China. This strategic approach aims to build on Xiuzheng's esteemed reputation in China and support its transition into a world-class global pharmaceutical group.

Reading history

Hide →

This history is cleared when the page is closed.

How will Cedrus Group facilitate market entry for foreign life sciences firms in China?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

2

0

0

Share with friends